Illumina (ILMN) reported $1.16 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 9.4%. EPS of $1.31 for the same period compares to $1.19 a year ago.

The reported revenue represents a surprise of +3.36% over the Zacks Consensus Estimate of $1.12 billion. With the consensus EPS estimate being $1.23, the EPS surprise was +6.5%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue by Source- Total product revenue- Sequencing: $900 million versus the four-analyst average estimate of $881.98 million. The reported number represents a year-over-year change of +7.7%.
  • Revenue- Product revenue- Total Consumable: $852 million versus $844.76 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
  • Revenue- Service and other revenue: $177 million versus the three-analyst average estimate of $162.77 million. The reported number represents a year-over-year change of +20.4%.
  • Revenue- Product revenue: $982 million compared to the $965.46 million average estimate based on three analysts. The reported number represents a change of +7.7% year over year.
  • Revenue- Product revenue- Total Instruments: $130 million compared to the $120.7 million average estimate based on three analysts. The reported number represents a change of +28.7% year over year.
  • Revenue- Consumables- Microarrays: $77 million versus the two-analyst average estimate of $79.2 million. The reported number represents a year-over-year change of +8.5%.
  • Revenue- Instruments- Sequencing: $125 million versus $118.04 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +30.2% change.
  • Revenue- Consumables- Sequencing: $775 million compared to the $763.94 million average estimate based on two analysts. The reported number represents a change of +4.7% year over year.
  • Revenue- Instruments- Microarrays: $5 million versus $4.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
  • Revenue by Source- Total product revenue- Microarray: $82 million versus $83.21 million estimated by two analysts on average.

View all Key Company Metrics for Illumina here>>>

Shares of Illumina have returned +5.9% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Illumina, Inc. (ILMN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research